Ligand	B:C0449982
dependent	I:C0449982
restoration	I:C0449982
of	O
human	B:C0086418
TLR3	B:C1336635
signaling	B:C1154413
and	O
death	B:C0007587
in	O
p53	B:C0079419
mutant	B:C0678941
cells	B:C0007634
.	O

Diversity	O
within	O
the	O
p53	B:C0079419
transcriptional	B:C1720950
network	I:C1720950
can	O
arise	O
from	O
a	O
matrix	O
of	O
changes	O
that	O
include	O
target	O
response	O
element	B:C0004793
sequences	I:C0004793
and	O
p53	B:C0079419
expression	B:C0017262
level	O
variations	O
.	O

We	O
previously	O
found	O
that	O
wild	B:C0079419
type	I:C0079419
p53	I:C0079419
(	O
wild	B:C0079419
type	I:C0079419
p53	I:C0079419
)	O
can	O
regulate	B:C0017263
expression	I:C0017263
of	O
most	O
innate	O
immune	O
-	O
related	O
Toll	B:C0017337
-	I:C0017337
like	I:C0017337
-	I:C0017337
receptor	I:C0017337
genes	I:C0017337
(	O
Toll	B:C0017337
-	I:C0017337
like	I:C0017337
-	I:C0017337
receptor	I:C0017337
genes	I:C0017337
)	O
in	O
human	B:C0427861
cells	I:C0427861
,	O
thereby	O
affecting	O
immune	B:C0301872
responses	I:C0301872
.	O

Since	O
many	O
tumor	B:C0027651
-	I:C0027651
associated	I:C0027651
p53	B:C0079419
mutants	B:C0678941
exhibit	O
change	B:C0040624
-	I:C0040624
of	I:C0040624
-	I:C0040624
spectrum	I:C0040624
transactivation	I:C0040624
from	O
various	O
p53	B:C0079419
targets	O
,	O
we	O
examined	O
the	O
ability	O
of	O
twenty	O
-	O
five	O
p53	B:C0079419
mutants	B:C0678941
to	O
activate	B:C0017262
endogenous	I:C0017262
expression	I:C0017262
of	O
the	O
TLR	B:C1517488
gene	I:C1517488
family	I:C1517488
in	O
p53	B:C0079419
null	O
human	B:C0086418
cancer	B:C0085983
cell	I:C0085983
lines	I:C0085983
following	O
transfection	B:C0314641
with	O
p53	B:C0079419
mutant	B:C0678941
expression	O
vectors	O
.	O

While	O
many	O
mutants	B:C0678941
retained	O
the	O
ability	O
to	O
drive	O
TLR	B:C0017262
expression	I:C0017262
at	O
WT	B:C1883559
levels	I:C1883559
,	O
others	O
exhibited	O
null	O
,	O
limited	O
,	O
or	O
change	B:C0040624
-	I:C0040624
of	I:C0040624
-	I:C0040624
spectrum	I:C0040624
transactivation	I:C0040624
of	O
TLR	B:C0017337
genes	I:C0017337
.	O

Using	O
TLR3	B:C1336635
signaling	B:C1154413
as	O
a	O
model	O
,	O
we	O
show	O
that	O
some	O
cancer	B:C0006826
-	O
associated	O
p53	B:C0079419
mutants	B:C0678941
amplify	O
cytokine	B:C0079189
,	O
chemokine	B:C0282554
and	O
apoptotic	B:C1817727
responses	I:C1817727
after	O
stimulation	O
by	O
the	O
cognate	B:C1749457
ligand	I:C1749457
poly	B:C0032414
(	I:C0032414
I:	I:C0032414
C	I:C0032414
)	I:C0032414
.	O

Furthermore	O
,	O
restoration	B:C0449982
of	O
wild	B:C0079419
type	I:C0079419
p53	I:C0079419
activity	O
for	O
loss	O
-	O
of	O
-	O
function	O
p53	B:C0079419
mutants	B:C0678941
by	O
the	O
p53	B:C0079419
reactivating	B:C1254351
drug	I:C1254351
RITA	I:C1254351
restored	O
p53	B:C0079419
regulation	B:C0017263
of	I:C0017263
TLR3	I:C0017263
gene	I:C0017263
expression	I:C0017263
and	O
enhanced	O
DNA	B:C0162638
damage	I:C0162638
-	I:C0162638
induced	I:C0162638
apoptosis	I:C0162638
via	O
TLR3	B:C1336635
signaling	B:C1154413
.	O

Overall	O
,	O
our	O
findings	O
have	O
many	O
implications	O
for	O
understanding	O
the	O
impact	O
of	O
WT	B:C0079419
and	O
mutant	B:C0678941
p53	B:C0079419
in	O
immunological	O
responses	O
and	O
cancer	B:C0920425
therapy	I:C0920425
.	O

